Science Pragmatism People Oriented

Liaoyuan Silver Eagle Pharmaceutical Co., Ltd The first "Sodium para-aminosalicylate" project certified by WHO

Liaoyuan Silver Eagle Pharmaceutical Co., Ltd The first "Sodium para-aminosalicylate" project certified by WHO On October 8, 2020, on the last day of the China National holiday of the double festival, Liaoyuan Silver Eagle Pharmaceutical received a letter from the World Health Organization, the company's product "Sodium Para-aminosalicylate" officially passed the WHO certification and registration. Become the first WHO enterprise of this product. Since Silver Eagle Pharmaceutical passed the WHO on-site PQT audit in July 2019, and since the site met the GMP production conditions, it has taken more than a year to keep improving and continuously improving the registration documents. And overcoming the difficulties during the epidemic, finally realized the historical breakthrough of Liaoyuan Silver Eagle certification and registration in WHO. Became the first pharmaceutical company in Liaoyuan City to pass the World Health Organization certification project. Sodium p-aminosalicylate is suitable for pulmonary and extrapulmonary tuberculosis caused by Mycobacterium tuberculosis. It is currently the main second-line anti-tuberculosis drug. Due to the incidence of tuberculosis, it is mainly concentrated in poor areas, resulting in low drug prices and small market supply. In recent years, there has been a shortage of market raw materials and serious shortages. Liaoyuan Silver Eagle upholds the principle of "Quality First, Customer First" and invested in the research and development and production of this project. It took 6 years from the establishment of the project to the receipt of certification and recognition from the World Health Organization. From R&D, testing, production, system construction, World Health Organization certification, hard work has been made, and the help from partners, thank all participants for their hard work and hard work. Liaoyuan Silver Eagle did not change its original intention to provide high-quality and efficient medicines for China and the world.